NCT05558982 - BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

November 30, 2027

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

BXCL701

BXCL701 0.3 mg, orally, twice a day on days 1-14 every 21 days

DRUG

Pembrolizumab

Pembrolizumab 200 mg intravenous (IV) on day 1 every 21 days.

Trial Locations (3)

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

Medstar Washington Hospital Center, Washington D.C.

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack